NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00703-3321-04 | 00703-3321 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Nov 14, 2005 | In Use | ||
63759-3032-01 | 63759-3032 | Bortezomib | Bortezomib | 3.5 mg/1.4mL | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | Sep 25, 2024 | In Use | |
55513-0126-10 | 55513-0126 | Epoetin alfa | Epogen | 2000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 30, 1989 | In Use | ||
55513-0478-10 | 55513-0478 | Epoetin alfa | Epogen | 20000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Mar 3, 1997 | In Use | ||
55513-0003-01 | 55513-0003 | Darbepoetin alfa | Aranesp | 40.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
25021-0465-01 | 25021-0465 | Octreotide acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Jun 15, 2023 | In Use | ||
55513-0025-04 | 55513-0025 | Darbepoetin alfa | Aranesp | 100.0 ug/.5mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug 14, 2006 | In Use | ||
55513-0004-04 | 55513-0004 | Darbepoetin alfa | Aranesp | 60.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
16714-0578-01 | 16714-0578 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Nov 18, 2022 | In Use | |
00078-0180-61 | 00078-0180 | Octreotide Acetate | Sandostatin | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug 13, 2012 | In Use | ||
55513-0002-04 | 55513-0002 | Darbepoetin alfa | Aranesp | 25.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
55513-0267-20 | 55513-0267 | Epoetin alfa | Epogen | 3000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Apr 14, 2025 | In Use | ||
00069-1318-04 | 00069-1318 | epoetin alfa-epbx | RETACRIT | 10000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Dec 1, 2020 | In Use | ||
55513-0053-01 | 55513-0053 | Darbepoetin alfa | Aranesp | 150.0 ug/.75mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
55513-0004-01 | 55513-0004 | Darbepoetin alfa | Aranesp | 60.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
00078-0182-61 | 00078-0182 | Octreotide Acetate | Sandostatin | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug 13, 2012 | In Use | ||
51817-0586-01 | 51817-0586 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 2, 2022 | In Use | |
00078-0180-01 | 00078-0180 | Octreotide Acetate | Sandostatin | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Oct 21, 1988 | In Use | ||
55513-0924-10 | 55513-0924 | Filgrastim | Neupogen | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Oct 2, 2000 | In Use | |
62756-0349-44 | 62756-0349 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Aug 14, 2007 | Nov 30, 2016 | No Longer Used | |
70860-0225-10 | 70860-0225 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 6, 2022 | Mar 31, 2025 | In Use |
63323-0379-05 | 63323-0379 | OCTREOTIDE ACETATE | Octreotide | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Mar 14, 2006 | In Use | ||
55150-0393-01 | 55150-0393 | AZACITIDINE | AZACITIDINE | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jan 3, 2023 | In Use | |
00781-3253-94 | 00781-3253 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Sep 16, 2013 | Feb 28, 2025 | No Longer Used |
59676-0310-02 | 59676-0310 | Erythropoietin | Procrit | 10000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 1, 1989 | In Use |
Found 11564 results — Export these results